What Attendees Can Expect from WCLC25 - IASLC / cancer, IASLC, International Association for the Study of Lung Cancer, Isabelle Schmitt-Opitz, Jarushka

Jarushka Naidoo Shares Duncan Preece’s Patient-Focused Insights from ALK Positive Canada / ALK Positive, cancer, Duncan Preece, Jarushka Naidoo, Lung Health

We report a pilot clinical trial investigating the feasibility of liquid biopsy genotyping (LBG) at the time of radiological suspicion of advanced NSCLC, incorporating a micro-cost model (MCM). (PLAsm...

YouTube video by European Society for Medical Oncology (ESMO)

This Viewpoint discusses the need to quantify the long-term adverse effects of immune checkpoint inhibitors, particularly immune-related adverse effects, which are not universally dose dependent, limi...

Abstract. Approved inhibitors of KRASG12C prevent oncogenic activation by sequestering the inactive, GDP-bound (OFF) form rather than directly binding and inhibiting the active, GTP-bound (ON) form. T...

This study examines a modified progressive disease classification and its association with postprogression survival in patients treated with atezolizumab across various solid tumors.

Abstract. Purpose: Patients with KRAS mutant non-small cell lung cancer (NSCLC) have limited therapeutic options. Based on activity of nuclear export inhibition in preclinical models, we evaluated thi...

Alectinib, a small-molecule kinase inhibitor, is used as first-line treatment for anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC). Albeit generally well-tolerated, a considerable subset of patients requires dose adjustments due to drug-related toxicity. Single-nucleotide polymorphisms (SNPs) in genes related to the metabolism of alectinib may upfront identify patients at risk for toxicity.